伊马替尼在RECIST进展期硬纤维瘤中诱导持续疾病进展停滞:德国跨学科肉瘤协作组(GISG)II期研究最终结果
这项II期研究纳入38例RECIST进展期、不可R0切除或切除将导致不可接受功能丧失的硬纤维瘤患者,每日口服伊马替尼800 mg计划治疗2年。6个月疾病进展停滞率(PAR6mo)为65%,24个月降至45%;伊马替尼进展后接受尼洛替尼800 mg/d的8例患者3个月PAR为88%。
要点
- RECIST进展期硬纤维瘤患者伊马替尼800 mg/d治疗6个月PAR为65%,24个月为45%。
- 研究观察期内无患者死亡,伊马替尼不良事件总体为轻至中度。
- 伊马替尼治疗后进展者接受尼洛替尼800 mg/d,8例中7例3个月无进展。
核心结论
- 伊马替尼可在RECIST进展期硬纤维瘤患者中诱导持续的疾病进展停滞。
- 尼洛替尼有潜力在伊马替尼治疗失败后稳定硬纤维瘤生长。
研究设计与样本
- 德国跨学科肉瘤协作组(GISG)开展的II期试验(NCT01137916),评估伊马替尼在RECIST进展期硬纤维瘤患者中诱导疾病进展停滞的效果。
- 入组患者为不适合以R0意图手术切除或手术伴随不可接受功能丧失者。
- 共38例患者接受伊马替尼每日800 mg、计划治疗2年;中位年龄44岁(范围19-80岁),女性占68%,ECOG体能状态0分者占90%。
- 主要终点为伊马替尼治疗6个月后的疾病进展停滞率(PAR6mo);伊马替尼治疗下疾病进展者可接受尼洛替尼每日800 mg。
- 2010年7月在4个GISG中心开始入组,2013年9月完成入组。
主要发现
- 全分析集可评估患者的主要终点最终分析显示PAR6mo为65%。
- 第9、12、15、18、21和24个月的后续疾病进展停滞率分别为65%、59%、53%、53%、50%和45%。
- 研究观察期内无患者死亡。
- 最佳报告缓解为21个月时7例部分缓解,总缓解率为19%。
- 8例接受尼洛替尼治疗的患者3个月疾病进展停滞率为88%(7/8),至研究结束无更多疾病进展。
关键数值与推荐
- 伊马替尼每日剂量800 mg,计划治疗2年。
- 尼洛替尼每日剂量800 mg,用于伊马替尼治疗下疾病进展的患者。
- 主要终点PAR6mo为65%;24个月疾病进展停滞率为45%。
- 总缓解率为19%(7例部分缓解,评估时间21个月)。
- 尼洛替尼3个月疾病进展停滞率为88%(7/8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Desmoid tumours describe a rare monoclonal, fibroblastic proliferation characterised by an often unpredictable clinical course. Surgery is one therapeutic option for progressing patients, except if mutilating and associated with considerable function loss. Different systemic treatment approaches have been investigated and promising results could be demonstrated using imatinib. PATIENTS AND METHODS: We initiated a phase II trial within the German Interdisciplinary Sarcoma Group (GISG) evaluating imatinib to induce progression arrest in desmoid tumour patients being Response Evaluation Criteria in Solid Tumours (RECIST) progressive, not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss (NCT01137916). Thirty-eight patients (median age 44 years [range: 19-80]; 68% female; 90% Eastern Cooperative Oncology Group (ECOG) performance status 0) were treated with a daily dose of 800 mg imatinib planned over 2 years. The progression arrest rate after 6 months of imatinib treatment (PAR6mo) was the primary end-point. Patients showing disease progression under imatinib could be treated with nilotinib 800 mg daily. Accrual started in July 2010 in four GISG centres and finalised in September 2013. RESULTS: The final analysis for the primary end-point in the evaluable patients of the full analysis set revealed a PAR6mo of 65%. Subsequent progression arrest rates at 9, 12, 15, 18, 21 and 24 months were 65%, 59%, 53%, 53%, 50% and 45%, respectively. None of the patients died within the study observational period. Best reported response was seven partial responses at 21 months revealing an overall response rate of 19%. Eight patients treated with nilotinib demonstrated a PAR at 3 months of 88% (7/8); no more disease progressions occurred until end of study. In general imatinib adverse events were mild to moderate. CONCLUSIONS: Imatinib induces sustained progression arrest in RECIST progressive desmoid tumour patients. In addition, nilotinib had the potential to stabilise desmoid tumour growth after treatment failure with imatinib.
引用
- Kasper B, Gruenwald V, Reichardt P, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017. PMID: 28282612. doi:10.1016/j.ejca.2017.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。